Stories
Slash Boxes
Comments

SoylentNews is people

posted by martyb on Friday August 17 2018, @05:26AM   Printer-friendly
from the don't-look-now dept.

After intense discussions regarding the ethical, legal, and social implications of this technology, conversations were initiated at the NIH that led to the establishment of the Recombinant DNA Advisory Committee (RAC) in 1974. The RAC's mission was to advise the NIH director on research that used emerging technologies involving manipulation of nucleic acids — a mission that was eventually expanded to encompass the review and discussion of protocols for gene therapy in humans. In 1990, the FDA oversaw the first U.S. human gene-therapy trial, which involved pediatric patients with adenosine deaminase deficiency and was conducted at the NIH Clinical Center in Bethesda, Maryland.

Although no major safety concerns were initially reported, over the course of the 1990s it became evident that many questions regarding the safety and efficacy of gene therapy remained unanswered. These unknowns were brought into sharp focus in 1999 when Jesse Gelsinger died of a massive immune response during a safety trial of gene therapy for ornithine transcarbamylase deficiency.1 This tragic death led to closer scrutiny of the field, including a greater focus on open dialogue and increased regulatory oversight.

[...] In changes proposed on August 17, 2018, in the Federal Register, the NIH and the FDA seek to reduce the duplicative oversight burden by further limiting the role of the NIH and RAC in assessing gene-therapy protocols and reviewing their safety information. Specifically, these proposals will eliminate RAC review and reporting requirements to the NIH for human gene-therapy protocols. They will also revise the responsibilities of institutional Biosafety Committees, which have local oversight for this research, making their review of human gene-therapy protocols consistent with review of other research subject to the NIH Guidelines. Such streamlining will also appropriately place the focus of the NIH Guidelines squarely back on laboratory biosafety.

Source: New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMp1810628


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 1, Troll) by realDonaldTrump on Friday August 17 2018, @01:30PM

    by realDonaldTrump (6614) on Friday August 17 2018, @01:30PM (#722786) Homepage Journal

    We’ve eliminated more regulations in less than 2 years than any administration has ever eliminated. And that means 4 years, 8 years or, in one instance, 16 years. And it is my opinion that the regulations had as big an impact as these massive tax cuts that we have given. I pledged to eliminate two unnecessary regulations for every one new regulation. If there's a new regulation, they have to knock out two. We have succeeded beyond our highest expectations. Instead of 2 for 1, we have cut 22 burdensome regulations for every new rule.

    And by the way, I want regulation. I want to protect our environment. I want regulations for safety. I want all of the regulations that we need and I want them to be so strong and so tough. But we don't need 75%, maybe more, of the repetitive, horrible regulations that hurt companies, hurt jobs. There will be regulation, there will be control, but it will be a NORMALIZED control where you can open your business and expand your business very easily. America is OPEN FOR BUSINESS!!!

    Starting Score:    1  point
    Moderation   -1  
       Troll=1, Total=1
    Extra 'Troll' Modifier   0  
    Karma-Bonus Modifier   +1  

    Total Score:   1